Reading this on a mobile device? Try our optimized mobile version here:

January 24, 2013News for the transfusion medicine and cellular therapy community

  Top Story 
  • Transfusions tied to immune system suppression in children
    Critically injured children who received blood transfusions had lower levels of the pro-inflammatory cytokine TNF-alpha, an indication the immune system is being repressed, according to a study presented at a critical care meeting. Their immune systems reverted to normal functioning sooner with the use of blood that was less than two weeks old. "Our findings provide evidence that storage age could play a role in modulating immune function in critically injured children, and we feel this is worthy of future studies," researcher Dr. Ryan Nofziger said. MedPage Today (free registration) (1/23) LinkedInFacebookTwitterEmail this Story
  • J&J considers potential sale or spinoff of Ortho Clinical Diagnostics
    Johnson & Johnson said it is exploring a possible sale or spinoff of its Ortho Clinical Diagnostics unit, which develops laboratory and blood transfusion testing tools. The company made the disclosure after reporting better-than-expected quarterly profits, driven by strong sales of its artificial hip and knee implants. Reuters (1/22) LinkedInFacebookTwitterEmail this Story
Digi-Trax® Corporation Helps Ensure your Facility's FDA Compliance
HemaTrax-UNITY is our newest blood bank software for printing ISBT 128 compliant labels. It works with your BBIS and can also be used as a standalone system — very useful for disaster recovery. Our single-source solution combines HemaTrax-UNITY software with printers, scanners, validation, labels and service. Learn more.

  Science & Health 
  • Gene therapy may boost patients' resistance to HIV
    Inserting three genes into the CCR5 receptor of T cells could strengthen a patient's immune resistance to HIV, a team of Stanford University scientists found. While the method is not a cure, it could help prevent the onset of AIDS, a researcher said. Trials could begin within five years, and the technique could have applications for sickle cell anemia, researchers said. The findings are to be published in the journal Molecular Therapy. (1/22) LinkedInFacebookTwitterEmail this Story
  • Coalition lifts H5N1 research moratorium
    According to a statement released Wednesday, a group of scientists is lifting a voluntary ban on avian influenza research that began in 2012 after two labs independently developed strains that passed easily between ferrets. The scientists said research should proceed only in nations that have developed policies for work with avian flu. A framework is being developed in the U.S. The Toronto Star (1/23) LinkedInFacebookTwitterEmail this Story
  • Drug-resistant bacteria are "a hidden epidemic"
    Bacteria are quickly becoming resistant to known antibiotics, and few new drugs are being developed to fill the void, experts say. Antibiotics are not as profitable for drugmakers as drugs to treat chronic diseases, so the federal government should develop a system to reward discovery and development of new antibiotics, says infectious disease specialist Jeffrey Jacobson. The Philadelphia Inquirer (1/22) LinkedInFacebookTwitterEmail this Story
  Emerging Trends 
  • Readmission rates at children's hospitals vary
    Overall, the 30-day unadjusted readmission rate for all children admitted at pediatric hospitals was 6.5%, but readmission rates varied across conditions and hospitals, U.S. researchers wrote in the Journal of the American Medical Association. Hospitals with high readmission rates had higher 30-day adjusted readmission rates and sickle cell rates than low-readmission hospitals, the study found. News (1/22) LinkedInFacebookTwitterEmail this Story
  Industry News & Practice 
  Government & Regulatory 
  Association News 
  • January issue of "AABB News" focuses on reimbursement
    The latest issue of "AABB News" explores the reimbursement landscape for transfusion services and cellular therapies. One article looks at emerging issues in this field -- such as new codes being recognized for molecular testing; medically unlikely edits; and an electronic database known as Logical Observation Identifiers Names and Codes, or LOINC. Another feature discusses reimbursement for cellular therapies, examining how specific treatments received coverage from government and private insurers. LinkedInFacebookTwitterEmail this Story
Learn more about AABB® ->Homepage  |  Join AABB  |  Conferences  |  Marketplace

Position TitleCompany NameLocation
Director of Reference & TransfusionCarter BloodcareUS - TX - Bedford
BLOOD BANK PROFESSIONALSHealthCare Connections, Inc.US - Nationwide
CTS Director Technical Training and Document SystemsCTS US - AZ - Tempe
Performance Improvement ConsultantBlood Systems, Inc.US - AZ - Scottsdale
Director of Quality SystemsRock River Valley Blood CenterUS - IL - Rockford
Clinical Lab Specialist IICreative Testing SolutionsUS - FL - St. Petersburg
Click here to view more job listings.

All news is an exaggeration of life."
--Daniel Schorr,
American journalist

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Corporate Relations Manager:  Tamara Zein (240) 333-6604
Job Board: AABB CareerLink
A powerful website for SmartBrief readers including:
 Recent AABB SmartBrief Issues:   Lead Editor:  Tom Parks
Managing Editor: Jennifer Garfinkel

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information